Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Non-Small-Cell Lung Cancer – Access & Reimbursement – Access & Reimbursement – Non-Small-Cell Lung Cancer (US)
The high number of premium-priced non-small-cell lung cancer (NSCLC) therapies and the large number of NSCLC patients have resulted in a significant financial burden for payers. Costs are set to…
Colorectal Cancer – Access & Reimbursement – Access & Reimbursement – Colorectal Cancer (US)
Seven premium-priced therapies (Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza) and three immune checkpoint inhibitors (Keytruda, Opdivo, and Yervoy) are FDA-approved to treat…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Current Treatment: Physician Insights – Squamous Cell Carcinoma of the Head and Neck (US)
Immune checkpoint inhibitors have transformed the treatment algorithm for recurrent or metastatic non-nasopharyngeal squamous cell carcinoma of the head and neck (SCCHN) and diversified treatment…
Squamous Cell Carcinoma of the Head and Neck – Current Treatment – Treatment Sequencing – Squamous Cell Carcinoma of the Head and Neck (US)
KEY BENEFITS AND USES Pinpoint current drug positioning and uptake in one snapshot to facilitate forecasting.Drill down into physicians’ treatment sequences and understand which drugs to position…
Non-Small-Cell Lung Cancer – Access & Reimbursement – Access & Reimbursement – Non-Small-Cell Lung Cancer (EU)
MARKET OUTLOOKNon-small-cell lung cancer (NSCLC) has a high incidence and a large number of premium-priced therapies, which results in a significant financial burden on payers. Costs are set to…
Breast Cancer – Access & Reimbursement – Access & Reimbursement – Optimizing Market Access Amid an Evolving Landscape for HR+/HER2- Therapies (EU)
MARKET OUTLOOKThe lucrative HR-positive, HER2-negative breast cancer market in Europe is fast-moving and competitive. CDK4/6 inhibitors Ibrance (Pfizer), Kisqali (Novartis) and Verzenios (Eli Lilly…
Ovarian Cancer – Access & Reimbursement – Access and Reimbursement – Ovarian Cancer (EU)
Market OutlookTargeted therapies are changing the treatment paradigm for ovarian cancer in the top 5 European markets (France, Germany, Italy, Spain, UK). Roche’s Avastin and small-molecule PARP…
Ovarian Cancer – Access & Reimbursement – Access & Reimbursement – Ovarian Cancer (US)
The premium-priced therapies used to treat ovarian cancer, such as Avastin (Roche/Genentech) and the PARP inhibitors Lynparza (AstraZeneca/Merck & Co), Rubraca (Clovis Oncology), and Zejula (…
Breast Cancer – Access & Reimbursement – Access & Reimbursement – Special Focus on Breast Cancer: Use of Clinical Pathways (US)
Market OutlookClinical pathways, which establish optimal treatment protocols for specific patient populations based on the best evidence, have become increasingly prevalent in the treatment of…
